Last updated: August 6, 2026
Rimegepant sulfate, marketed as Nurtec ODT in the United States and Vydura in some international markets, is Pfizer's oral calcitonin gene-related peptide, or CGRP, antagonist for acute and preventive migraine treatment. The product generated approximately $928 million in Pfizer revenue in 2023 and reached roughly $1 billion in 2024, making it one of Pfizer's more important growth products outside its COVID-19 portfolio. Its commercial position is supported by dual acute and preventive indications, an orally disintegrating formulation, and broad physician familiarity. Its principal risks are CGRP-class competition, payer controls, generic ANDA litigation, and eventual erosion of its patent-protected revenue base.
What is rimegepant sulfate and how is Nurtec ODT used?
Rimegepant sulfate is the sulfate salt of rimegepant, a small-molecule CGRP receptor antagonist. Nurtec ODT is supplied as a 75 mg orally disintegrating tablet.
| Attribute |
Detail |
| Active ingredient |
Rimegepant sulfate |
| Brand |
Nurtec ODT in the United States; Vydura in certain markets |
| U.S. sponsor |
Pfizer, through the Biohaven acquisition |
| U.S. NDA |
NDA 212728 |
| Dosage form |
75 mg orally disintegrating tablet |
| Acute indication |
Treatment of migraine with or without aura in adults |
| Preventive indication |
Preventive treatment of episodic migraine in adults |
| Administration |
One 75 mg tablet for acute treatment; 75 mg every other day for prevention |
| FDA acute approval |
February 2020 |
| FDA preventive approval |
May 2021 |
| Regulatory pathway |
Small-molecule NDA, not a biologic |
The ODT formulation allows administration without water and differentiates Nurtec from conventional swallowed tablets. The product does not require injection, which gives it a convenience advantage over injectable CGRP antibodies such as Aimovig, Ajovy and Emgality.
How has the rimegepant market developed?
Rimegepant competes in the expanding CGRP migraine market, which includes oral gepants and injectable monoclonal antibodies. The market has shifted from acute-only treatment toward preventive therapy, where patients may remain on treatment for extended periods.
The key commercial segments are:
- Acute migraine treatment
- Episodic migraine prevention
- Patients who do not respond adequately to triptans
- Patients who cannot tolerate triptans
- Patients who prefer oral treatment over injections
- Patients using a single product for both acute and preventive therapy
Nurtec's main branded competitors include Ubrelvy and Qulipta from AbbVie, Aimovig from Amgen and Novartis, Ajovy from Teva, and Emgality from Eli Lilly.
How does Nurtec compare with competing CGRP drugs?
| Product |
Company |
Active ingredient |
Primary role |
Formulation |
Commercial distinction |
| Nurtec ODT |
Pfizer |
Rimegepant |
Acute and preventive |
Oral disintegrating tablet |
Dual indication and no-water administration |
| Ubrelvy |
AbbVie |
Ubrogepant |
Acute |
Oral tablet |
Direct acute-treatment competitor |
| Qulipta |
AbbVie |
Atogepant |
Preventive |
Oral tablet |
Preventive-only oral gepant |
| Aimovig |
Amgen/Novartis |
Erenumab |
Preventive |
Injectable antibody |
Monthly or quarterly administration depending on dose |
| Ajovy |
Teva |
Fremanezumab |
Preventive |
Injectable antibody |
Monthly or quarterly administration |
| Emgality |
Eli Lilly |
Galcanezumab |
Preventive and cluster headache |
Injectable antibody |
Preventive and cluster-headache positioning |
Nurtec has an important portfolio advantage over Ubrelvy because it covers both acute treatment and prevention. AbbVie's Qulipta reduces that advantage in the preventive market, while Ubrelvy remains a direct competitor for acute treatment.
What is the financial trajectory for rimegepant and Nurtec ODT?
Pfizer's public reporting indicates rapid revenue growth after the company acquired Biohaven's commercial migraine business in 2022.
| Period |
Reported or estimated Nurtec/Vydura revenue |
Commercial interpretation |
| 2021 |
Approximately $462 million in Biohaven net product revenue |
Pre-acquisition growth phase |
| 2022 |
Not directly comparable because Pfizer acquired the product during the year |
Transition year |
| 2023 |
Approximately $928 million |
Strong full-year Pfizer contribution |
| 2024 |
Approximately $1.0 billion to $1.1 billion |
Continued growth, but at a more mature rate |
| 2025 onward |
Dependent on access, class competition and generic timing |
Growth should moderate as the brand matures |
Biohaven reported Nurtec net product revenue of approximately $462 million in 2021. Pfizer completed its acquisition of Biohaven's commercialized portfolio in October 2022 after the parties separated Biohaven's commercial and pipeline assets. Pfizer then assumed global commercialization rights for Nurtec and related products in most markets.[1][2]
The 2023 revenue figure of approximately $928 million reflected continued prescription growth, expanded preventive use and Pfizer's larger commercial infrastructure. Revenue growth after 2023 depends less on initial product adoption and more on refill persistence, payer coverage, preventive-treatment penetration and international commercialization.
What drives rimegepant revenue?
The most important revenue drivers are:
- Dual acute and preventive labeling.
- Growth in patients receiving preventive migraine therapy.
- Expansion of CGRP use after inadequate response to triptans.
- Increased use among patients who prefer oral therapy.
- Pfizer's contracting, market-access and specialty-pharmacy capabilities.
- Refill persistence among preventive patients.
- Reduced reliance on manufacturer savings programs over time.
Pricing growth is less reliable than volume growth because commercial payers and pharmacy benefit managers commonly require prior authorization, step therapy or failure of lower-cost alternatives. Net sales therefore depend on gross-to-net discounts, rebates and patient-support programs as well as prescription volume.
When did Pfizer acquire rimegepant rights from Biohaven?
Pfizer acquired Biohaven's commercial portfolio for approximately $11.6 billion in cash in 2022. The transaction gave Pfizer commercial rights to Nurtec ODT/Vydura and related rimegepant assets outside the territories retained by Biohaven's new company.
The transaction was strategically important because Pfizer obtained a marketed CGRP product with:
- An established U.S. prescription base
- Both acute and preventive indications
- An oral dosage form
- A high-growth migraine market
- A commercial platform that could be integrated into Pfizer's specialty-care operations
Biohaven retained certain rights and pipeline assets through the separation transaction, while Pfizer became the principal commercial owner of Nurtec in the United States and multiple international markets.[2]
What FDA regulatory status applies to rimegepant?
Nurtec ODT is FDA-approved under NDA 212728. The FDA approved the product in February 2020 for acute treatment of migraine in adults. In May 2021, the FDA expanded the label to include preventive treatment of episodic migraine in adults.[3]
The approval profile creates a stronger commercial position than an acute-only product because preventive patients may use the drug on a recurring schedule. The preventive regimen is one 75 mg dose every other day, while the acute indication uses one 75 mg dose as needed, subject to labeling limits.
Rimegepant is a small molecule. It is therefore exposed to conventional generic competition through abbreviated new drug applications, or ANDAs, rather than biosimilar competition under the Biologics Price Competition and Innovation Act.
What patents protect rimegepant sulfate and Nurtec ODT?
The Nurtec patent estate includes composition-of-matter, pharmaceutical composition, formulation and method-of-use rights. The controlling commercial protection is expected to extend well beyond the initial 2020 approval date through a combination of listed patents, patent-term adjustment, pediatric exclusivity where applicable, and later-issued patents.
The principal patent categories are:
| Patent category |
Protected subject matter |
Competitive effect |
| Compound patents |
Rimegepant chemical entities and related salts |
Core active-ingredient protection |
| Composition patents |
Pharmaceutical compositions containing rimegepant |
Limits certain generic formulations |
| Formulation patents |
Orally disintegrating or rapidly dissolving dosage forms |
Raises barriers for ODT copies |
| Method-of-use patents |
Acute migraine and preventive migraine treatment |
Can support infringement litigation after composition patents expire |
| Manufacturing patents |
Processes, intermediates or solid forms |
May complicate non-infringing manufacture |
The FDA Orange Book should be treated as the controlling source for patents listed against NDA 212728, including patent numbers, expiration dates and any pediatric exclusivity adjustments.[4] Patent coverage can change as patents issue, expire, are delisted or are affected by litigation outcomes. Commercial forecasting should therefore distinguish between the earliest possible generic launch date, the latest listed patent date and any settlement-based launch date.
When does rimegepant lose exclusivity?
Rimegepant does not have a single exclusivity date. Its market protection is determined by overlapping regulatory and patent rights.
Regulatory exclusivity
The product received approval in 2020, so its five-year new chemical entity exclusivity period generally expired in 2025. That period blocked submission of an ANDA relying on the rimegepant NDA during the initial statutory window, subject to applicable regulatory rules.
The 2021 preventive indication did not create a new five-year NCE exclusivity period. Any three-year exclusivity associated with new clinical investigations would protect only the approved condition of use and would not necessarily prevent all generic rimegepant approvals.
Patent exclusivity
The effective generic entry date is likely controlled by listed patents extending into the 2030s, not by the 2020 regulatory exclusivity period. The most commercially important patents are those covering the rimegepant compound and the Nurtec ODT formulation.
Potential generic entry may occur through:
- A successful Paragraph IV challenge
- A settlement allowing an agreed launch date
- A later generic launch after all relevant patents expire
- A carve-out that omits a protected preventive or acute indication
- A non-infringing dosage form or manufacturing process
A generic could receive approval with a Section viii statement that removes a patented method of use from its labeling, but this strategy would not automatically avoid composition or formulation patents.
Which companies are challenging Nurtec patents?
Generic challenges are expected to involve ANDA filers seeking approval for rimegepant tablets or orally disintegrating formulations. Public litigation records and FDA Orange Book certifications should be monitored for cases involving Pfizer, Biohaven-related entities and generic applicants.
Potential challengers in this market include large generic companies such as Teva, Sandoz, Dr. Reddy's, Hetero, Zydus and Apotex. The identity of a challenger, the patents certified under Paragraph IV and the filing date of the related patent litigation determine the timing of any 30-month stay.
A Paragraph IV certification can trigger patent litigation within 45 days. If the brand owner files suit within that period, FDA approval may be stayed for up to 30 months, subject to court decisions, settlement, patent expiration or other statutory events.[5]
What patent litigation and settlement risks affect rimegepant?
The main litigation issues are likely to concern:
- Validity of compound patents
- Obviousness of the rimegepant molecule or salt
- Written description and enablement
- Scope of ODT formulation claims
- Infringement by generic dosage forms
- Carve-outs for acute or preventive treatment
- Patent-term adjustment calculations
- Whether later-issued patents are enforceable against an ANDA product
A settlement can preserve substantial branded revenue while allowing a generic launch before the final patent expiration date. Financial models should use at least three scenarios:
| Scenario |
Launch timing |
Revenue effect |
| Full patent defense |
After the last enforceable patent |
Highest protection and slowest erosion |
| Settled entry |
Agreed date before final patent expiry |
Gradual erosion before legal expiry |
| Early invalidity or non-infringement win for generic |
Shortly after litigation |
Sharp price and volume pressure |
What generic entry risks exist for rimegepant?
Rimegepant faces a conventional small-molecule generic risk profile rather than biosimilar substitution risk. The principal risk is not only the approval of a generic active ingredient. It is the ability of a generic manufacturer to reproduce the ODT product, obtain comparable bioavailability, satisfy quality requirements and avoid enforceable formulation claims.
The highest-risk period begins when:
- The earliest compound patent expires or is invalidated.
- A major generic filer obtains an approval pathway.
- A court narrows the scope of the ODT claims.
- A settlement permits an authorized or independent generic launch.
- Payers remove prior authorization barriers for generic rimegepant.
Generic erosion for an oral migraine product can be rapid once multiple manufacturers enter. Payers may prefer the lowest-net-cost product, and switching is operationally easier than with injectable biologics.
What manufacturing and intellectual-property barriers protect rimegepant?
Manufacturing barriers are weaker than for complex biologics but remain relevant. Rimegepant manufacturers must control:
- API purity and impurity profiles
- Salt formation
- Solid-state properties
- Tablet disintegration
- Taste and mouthfeel
- Stability under packaging conditions
- Dose uniformity
- Bioequivalence for the ODT dosage form
The ODT presentation may provide more protection than a conventional immediate-release tablet because generic manufacturers must address the same dissolution, disintegration and patient-acceptability requirements. Pfizer may also rely on trade secrets involving manufacturing process controls, supplier qualification and product-scale production.
How strong is the rimegepant patent estate?
The estate is commercially strong but not immune to challenge.
Strengths include:
- A valuable composition-of-matter position
- A distinct orally disintegrating formulation
- Two major migraine indications
- Multiple patent categories
- High commercial value that supports litigation spending
- Pfizer's ability to defend the product globally
Weaknesses include:
- Small-molecule ANDA substitution
- Potential obviousness challenges
- The possibility of skinny-label generic approval
- Multiple potential generic filers
- The absence of biologic interchangeability barriers
- Payer pressure once a generic becomes available
The most important question is whether the compound and formulation patents can sustain exclusivity into the mid-to-late 2030s. The answer must be based on the current Orange Book record and litigation results rather than on the product's original 2020 approval date.
What is the competitive outlook for Nurtec ODT?
Nurtec is positioned between acute-treatment gepants and preventive therapies. AbbVie's Ubrelvy and Qulipta create the strongest direct competitive pressure because AbbVie can offer a broader oral CGRP portfolio. Injectable antibodies retain a role among patients seeking monthly or quarterly dosing, while triptans remain important because of low cost and broad availability.
Nurtec's strongest commercial advantages are:
- One product for acute and preventive use
- No injection requirement
- ODT administration
- Established payer and prescriber familiarity
- Pfizer's global commercial reach
Its principal disadvantages are:
- High branded net cost compared with triptans
- Prior authorization and step-edit requirements
- Competition from Qulipta in prevention
- Competition from Ubrelvy in acute treatment
- Future generic substitution
- Potential class-level price competition
What revenue exposure does Pfizer have to rimegepant?
At approximately $1 billion in annual sales, Nurtec is material to Pfizer but is not large enough to determine the company's overall performance. The product is more important as a growth and diversification asset than as a single-company revenue concentration risk.
Revenue exposure is concentrated in the United States, where migraine diagnosis, CGRP prescribing and insurance access are most developed. International sales add geographic diversification but generally face lower prices, slower reimbursement decisions and country-specific reference pricing.
The key valuation variables are:
- Annual prescription growth
- Preventive-treatment share
- Net price after rebates
- Refill persistence
- New competitor launches
- Generic entry timing
- Settlement terms
- Patent validity
- Pfizer's ability to retain patients after payer restrictions
Key Takeaways
- Rimegepant sulfate is marketed as Nurtec ODT and is approved for both acute migraine treatment and episodic migraine prevention.
- Pfizer acquired the commercial product from Biohaven in 2022 for approximately $11.6 billion.
- Revenue grew from approximately $462 million in Biohaven's 2021 reporting period to approximately $928 million in Pfizer's 2023 reporting period and roughly $1 billion in 2024.
- The product's commercial value comes from dual indication coverage, oral ODT administration and strong positioning within the CGRP class.
- Rimegepant is a small molecule, so future competition will arise through ANDAs rather than biosimilars.
- The five-year NCE exclusivity period has ended, but patent protection is expected to remain the principal barrier to generic entry.
- Compound, formulation and method-of-use patents should be reviewed through the current FDA Orange Book and federal litigation docket.
- AbbVie's Ubrelvy and Qulipta are the most important oral competitors.
- Generic entry could produce rapid price and volume erosion because payer substitution for an oral product is relatively straightforward.
- The principal investment question is the enforceable generic launch date, not the initial 2020 FDA approval date.
FAQs About Rimegepant Sulfate
Is rimegepant sulfate the same as Nurtec ODT?
Yes. Rimegepant sulfate is the active pharmaceutical ingredient in Nurtec ODT, the Pfizer-branded 75 mg orally disintegrating tablet.
Does rimegepant have biosimilar competition?
No. Rimegepant is a small molecule. Competition will proceed through generic-drug pathways, primarily ANDAs, rather than biosimilar applications.
Can rimegepant be used for both migraine attacks and prevention?
Yes. The FDA approved rimegepant for acute treatment in 2020 and episodic migraine prevention in 2021.
What is the main commercial threat to Nurtec ODT before generic entry?
The main threat is branded CGRP competition, particularly AbbVie's Ubrelvy for acute treatment and Qulipta for prevention, combined with payer restrictions and rebate pressure.
What determines the first possible generic launch date for rimegepant?
The date depends on the Orange Book patent estate, any Paragraph IV litigation, court rulings, patent-term adjustments, pediatric exclusivity and settlement agreements between Pfizer and generic applicants.
References
-
Biohaven Pharmaceutical Holding Company Ltd. (2022). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. U.S. Securities and Exchange Commission.
-
Pfizer Inc. (2022). Pfizer to acquire Biohaven Pharmaceutical Holding Company Ltd.'s commercialized migraine portfolio. https://www.pfizer.com/news/press-release/press-release-detail/pfizer-acquire-biohaven-pharmaceutical-holding-company-ltds
-
U.S. Food and Drug Administration. (2021). FDA approves new treatment for preventive treatment of migraine. https://www.fda.gov
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
-
U.S. Food and Drug Administration. (2024). Hatch-Waxman amendments and abbreviated new drug applications. https://www.fda.gov/drugs/abbreviated-new-drug-application-anda/hatch-waxman-amendments-and-abbreviated-new-drug-applications
-
Pfizer Inc. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. U.S. Securities and Exchange Commission.
